

# Systematic Overview of Warfarin and Its Drug and Food Interactions

Anne M. Holbrook, MD, PharmD, MSc, FRCPC; Jennifer A. Pereira, MSc; Renee Labiris, PhD; Heather McDonald, MSc; James D. Douketis, MD, FRCPC; Mark Crowther, MD, MSc, FRCPC; Philip S. Wells, MD, FRCPC

**Background:** Warfarin is a highly efficacious oral anticoagulant, but its use is limited by a well-founded fear of bleeding. Drug and food interactions are frequently cited as causes of adverse events with warfarin. We provide an updated systematic overview of the quality, clinical effect, and importance of these reported interactions.

**Data Sources:** MEDLINE, TOXLINE, IPA, and EMBASE databases from October 1993 to March 2004. Database searches combined the keyword *warfarin* with *drug interactions*, *herbal medicines*, *Chinese herbal drugs*, and *food-drug interactions*.

**Study Selection:** Eligible articles contained original reports of warfarin drug or food interactions in human subjects. Non-English articles were included if sufficient information could be abstracted.

**Data Extraction:** Reports were rated independently by 2 investigators for interaction direction, clinical severity, and quality of evidence. Quality of evidence was based on previously validated causation criteria and study design.

**Data Synthesis:** Of 642 citations retrieved, 181 eligible articles contained original reports on 120 drugs or foods. Inter-rater agreement was excellent, with weighted  $\kappa$  values of 0.84 to 1.00. Of all reports, 72% described a potentiation of warfarin's effect and 84% were of poor quality, 86% of which were single case reports. The 31 incidents of clinically significant bleeding were all single case reports. Newly reported interactions included celecoxib, rofecoxib, and herbal substances, such as green tea and danshen.

**Conclusions:** The number of drugs reported to interact with warfarin continues to expand. While most reports are of poor quality and present potentially misleading conclusions, the consistency of reports of interactions withazole antibiotics, macrolides, quinolones, nonsteroidal anti-inflammatory drugs, including selective cyclooxygenase-2 inhibitors, selective serotonin reuptake inhibitors, omeprazole, lipid-lowering agents, amiodarone, and fluorouracil, suggests that coadministration with warfarin should be avoided or closely monitored. More systematic study of warfarin drug interactions in patients is urgently needed.

*Arch Intern Med.* 2005;165:1095-1106

**Author Affiliations:** Centre for Evaluation of Medicines, St Joseph's Healthcare, Hamilton, Ontario (Drs Holbrook and Labiris and Ms Pereira); Department of Medicine, McMaster University, Hamilton (Drs Holbrook, Labiris, Douketis, and Crowther); Department of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario (Dr Holbrook and Ms Pereira); Axon Clinical Research, Toronto (Ms McDonald) and Ottawa Civic Hospital Research Centre, Ottawa, Ontario (Dr Wells).  
**Financial Disclosure:** None.

# W

ARFARIN IS THE MOST commonly used oral anticoagulant in North America and has established efficacy for the prevention of thromboembolic events in patients with chronic atrial fibrillation, prosthetic heart valves,

## See also page 1185

venous thromboembolism, and coronary artery disease.<sup>1-4</sup> The drug is a racemic mixture of 2 optically active isomers, though the S-enantiomer is approximately 5 times more potent than the R-enantiomer. Warfarin exerts its effect by lowering the amount of active vitamin K available for the activation of clotting factors II, VII, IX,

and X.<sup>5</sup> Both effectiveness and safety (primarily risk of bleeding) are related to blood international normalized ratio (INR) values. Monitoring of INR and dose adjustments of warfarin are frequently required, influenced by changes in concomitant medications, diet, alcohol consumption, acute illness, liver disease, and unknown factors.<sup>5</sup>

## CME course available at [www.archinternmed.com](http://www.archinternmed.com)

Despite the frequency and importance of warfarin's drug and food interactions, the first systematic overview on the topic did not appear until 1994.<sup>6</sup> For that review, we developed an interaction assessment tool that combined a "levels of evi-

**Table 1. Quality of Study Design**

| Quality   | Study Design                                       |
|-----------|--|
| Excellent | RCTs with >100 subjects                            |
| Good      | RCTs with 20-100 subjects                          |
| Fair      | RCTs with <20 subjects                             |
| Poor      |  |
| Group 1   | Observational studies (cohort, case-control)       |
| Group 2   | Case series, case reports, pharmacokinetic studies |

Abbreviation: RCTs, randomized controlled trials.

dence” approach with causation criteria, subject outcome, and proposed mechanisms. Although many drugs, including antibiotics, drugs affecting the central nervous system, and cardiac medications, had been reported to interact with warfarin, the quality of reports was so poor that few clinical recommendations could be made other than careful monitoring around initiating and discontinuing treatment with other medications. In the decade since that review, awareness and investigation of drug interactions and quality of evidence have grown, leading to the hypothesis that the number and quality of drug and food interactions would increase as well. We therefore performed a systematic overview of the literature, updating the evidence on warfarin drug and food interactions.

## METHODS

Relevant literature was identified by searching MEDLINE, TOXLINE, IPA, EMBASE databases, Health Canada and Food and Drug Administration Web sites and personal files from October 1993 to the end of March 2004. The MeSH headings and keywords used for the search were *warfarin* and *drug interactions*. Non-English articles were included if they included an English abstract with sufficient information. To retrieve warfarin-herbal drug interactions and warfarin-food interactions, 2 additional searches were conducted using the MeSH headings and keywords *warfarin* and *herbal medicines* or *Chinese herbal drugs*, and MeSH headings *food-drug interactions* and *warfarin*, limited to English only. The bibliographies of the retrieved articles were checked for any additional pertinent studies. Articles were considered eligible for evaluation if they contained original data involving drug or

food interactions with warfarin in human subjects. Interacting drugs had to be available in the United States or Canada. Eligible studies were evaluated independently by 2 authors according to the following 4 main categories.

## SUBJECT

Subjects were classified as patients or healthy volunteers. Patients were then further stratified into 2 categories: volunteers and nonvolunteers. The former group were defined as patients requiring warfarin therapy who were prospectively entered into a study, whereas the latter group was exposed to the interacting drug during the course of usual warfarin therapy. Healthy volunteers were healthy individuals not requiring warfarin therapy.

## INTERACTION CLASSIFICATION AND SEVERITY

The drug affected and the type of interaction (potentiation, inhibition, or no effect) were noted. Interactions that potentiated or inhibited the effect of warfarin were further rated as major, moderate, minor, or nonclinical.

Major potentiation was defined by death, major bleeding, or necessity to stop warfarin therapy entirely. Major bleeding episodes included those that were life-threatening as well as those that led to the loss of at least 2 units of blood in 7 days or less.<sup>7</sup> Moderate potentiation meant that (1) there was an INR change requiring an adjustment in warfarin dosage or (2) the INR increased to greater than 5.0 or (3) there was an increase in INR by greater than 1.5. Minor potentiation interactions were defined as an INR increase in which (1) no change in warfarin dosage was required and (2) the ratio remained less than 5 and (3) the increase was less than 1.5. Potentiation interactions were classified as nonclinical if the only evidence of warfarin augmentation was a statistically significant increase in warfarin levels without change in INR or clinical status.

Major inhibition interactions were defined by the occurrence of thrombosis. Moderate inhibition (clinically relevant but less than major) indicated (1) a change in INR requiring an adjustment in warfarin dosage or (2) an INR decrease to less than 1.5 or (3) a decrease in INR by greater than 1.5 units. Minor inhibition interactions were defined by (1) an INR decrease requiring no change in warfarin dosage and (2) an INR decrease to a ratio that remained

more than 1.5 and (3) a decrease in INR by less than 1.5. Inhibition interactions were classified as nonclinical if the only evidence of warfarin inhibition was a statistically significant decrease in warfarin levels.

An interaction was defined as having no effect if the interacting drug neither potentiated nor inhibited warfarin's effect in any way described herein.

## QUALITY OF STUDY

Reports were classified into 1 of 4 categories based on the quality of study design. As shown in **Table 1**, randomized controlled trials (RCTs) were subdivided into fair to excellent quality, with those involving more than 100 subjects arbitrarily given the highest rating. Poor quality reports included non-randomized study designs, observational studies, pharmacokinetic studies, and case reports.

## CAUSATION CRITERIA

For each report, the probability of the proposed interaction was rated from level I (highly probable) to level IV (highly improbable). Definitive evidence of an interaction required a level I causation rating from both healthy volunteer and patient-based reports in which both described identical interaction direction and severity. Level designation was based on how the article fulfilled 7 standard causation criteria.

| Level of Causation     | Causation Criteria Required          |
|------------------------|--------------------------------------|
| I (Highly probable)    | A, B, C, and $\geq 1$ of D to G      |
| II (Probable)          | A, B, and $\geq 1$ of C to G         |
| III (Possible)         | A and $\geq 1$ of B to G             |
| IV (Highly improbable) | A alone or any combination of B to G |

A. Is the timing correct for an interaction to be pharmacologically plausible?

In patient-based studies, warfarin must have been taken at a stabilized dose common to usual practice and prior to initiation of the interacting drug or food. For volunteer-based studies, subjects had to have received warfarin, both alone as well as with the interacting drug. In addition, we required that the potentially interacting drug had to be consumed (1) long enough to attain a significant plasma level and (2) in doses common to usual practice.

B. Do laboratory tests (eg, international normalized ratio/prothrombin time/thrombotest) support the contention of an interaction?

In patient-based articles, the post-coadministration coagulation variable

had to be out of therapeutic range, whereas for volunteer studies, a 20% change in coagulation parameters for volunteer studies was required. For articles concluding “no interaction,” the absence of a statistically significant change in coagulation variables was required.

C. Are other potential factors affecting warfarin pharmacokinetics/pharmacodynamics ruled out satisfactorily?

Factors such as diet, other medications, as well as certain medical conditions (hepatic dysfunction and hyperthyroidism) had to have been declared to be ruled out as possible causes of the outcome.

D. Has the patient had a similar result with previous exposure to the same drug?

The patient had to have been taking the interacting drug in addition to warfarin at a time prior to that reported with a similar outcome.

E. Was a dose-response relationship demonstrated for the interacting drug? The alterations in the dose of the implicated interacting drug or food being administered with warfarin correlated with subsequent changes in coagulation variables, inferring a dose-response relationship.

F. Was the subject rechallenged and, if so, did a similar response occur?

The interacting drug had to have been administered simultaneously with warfarin in 2 or more separate courses (the second course conducted to confirm the results of the first), with similar results each time.

G. Are the authors' conclusions supported by other objective evidence?

Other objective evidence such as plasma levels of warfarin or coagulation factors supported the authors' conclusions.

## RELIABILITY AND VALIDITY

The criteria and rating scheme were evaluated and approved a priori by a panel of experts in the fields of thromboembolism, clinical pharmacology, and clinical epidemiology to assure face validity. Interrater agreement for interaction direction and severity, quality of study, and level of causation was assessed using a weighted  $\kappa$  statistic.<sup>8</sup>

## CONFLICTING EVIDENCE

If ratings differed among articles for the same interacting drug or food, a hierarchy was implemented (type of subject > quality of study > level of causation > severity of clinical outcome). For example, a case report involving a patient was considered to be su-

perior to an RCT using healthy volunteers as subjects. If 2 or more articles had the same subject type, the result of the highest quality study was listed—a patient-based RCT was considered superior to a patient case report. If 2 or more articles with the same subject type and quality of study varied in level of causation and clinical outcome, the clinical outcome associated with the highest level of evidence was listed. For example, the case report describing moderate potentiation of warfarin by celecoxib, with a level II causation rating<sup>9</sup> outweighed the level III case report describing a similar interaction.<sup>10</sup> For 2 level III causation patient case reports describing amoxicillin's effect on warfarin, the report describing major potentiation<sup>11</sup> outweighed the one describing moderate potentiation.<sup>11</sup>

## RESULTS

A total of 642 citations were identified, of which 205 contained original data on drug or food interactions with warfarin. Of these 205 articles, 181 were retrievable and available for review. The reviewed articles contained 187 separate reports of interactions involving 120 drugs or foods. The weighted  $\kappa$  statistic for the interaction direction and severity rating, level of causation evaluation, and quality of study rating among the reviewers were 0.98, 0.84, and 1.0 respectively. All rating disagreements were resolved by repeated review and consensus.

No study met our definition of excellent quality. Thirty-three small RCTs were rated fair or good quality, of which 28 involved healthy subjects and 26 concluded a lack of interaction between warfarin and the drug or food studied. Olestra,<sup>12</sup> vitamin E,<sup>13</sup> clopidogrel,<sup>14</sup> coenzyme Q10/ginkgo biloba 10,<sup>15</sup> and ciprofloxacin<sup>16</sup> were the only drugs for which patient-based RCTs were conducted, with a “no effect” conclusion for olestra, vitamin E, clopidogrel, and coenzyme Q10/ginkgo biloba and nonclinical potentiation for ciprofloxacin. Of the reviewed studies, 148 (82%) were rated poor quality and 130 (88%) of these were case reports, of which 125 (96%) were single case reports.

Forty-one new reports were rated as level I causation (highly probable) for an interaction, with 14 reporting potentiation (acetami-

nophen,<sup>17</sup> boldo-fenugreek,<sup>18</sup> ciprofloxacin,<sup>16</sup> citalopram,<sup>19</sup> diltiazem,<sup>20</sup> entacapone,<sup>21</sup> fenofibrate,<sup>22</sup> fish oil,<sup>23</sup> mango,<sup>24</sup> miconazole vaginal suppositories,<sup>25</sup> quillingao,<sup>26</sup> sertraline,<sup>27</sup> voriconazole,<sup>28</sup> and zileuton<sup>29</sup>), 5 reporting inhibition (etodolac,<sup>30</sup> mercaptopurine,<sup>31</sup> mesalamine,<sup>32</sup> ribavirin,<sup>33</sup> and trazodone<sup>34</sup>), and 22 reporting “no effect” (anastrozole,<sup>35</sup> argatroban,<sup>36</sup> cilostazol,<sup>37</sup> clopidogrel,<sup>14</sup> donepezil hydrochloride,<sup>38</sup> eprosartan,<sup>39</sup> entacapone,<sup>40</sup> gemifloxacin,<sup>41</sup> levetiracetam,<sup>42</sup> losartan,<sup>43</sup> meloxicam,<sup>44</sup> metrifonate,<sup>45</sup> miglitol,<sup>46</sup> modafinil,<sup>47</sup> moexipril,<sup>48</sup> montelukast,<sup>49</sup> nateglinide,<sup>50</sup> nefazodone,<sup>51</sup> oles- tra,<sup>12</sup> pantoprazole,<sup>52</sup> sevelamer hydrochloride,<sup>53</sup> and vitamin E<sup>13</sup>).

For 38 drugs or foods, level II causation (probable) criteria were met, and for the remaining 41 drugs or foods, the evidence was even less conclusive. Only 57 (31%) of the studies ruled out potential confounders, and fewer than 20% of the articles provided rechallenge data, demonstration of a dose response relationship, or a description of a previous exposure in which the patient experienced a similar effect.

Of all 184 reviewed reports, 128 (70%) described a potentiation of warfarin's effect, while inhibition and “no effect” reports each comprised 28 (15%). There were 34 reports of a major interaction—3 case reports of thrombosis associated with trazodone, sulfasalazine, and propofol and 31 case reports describing a major potentiation. These included 8 deaths, 4 of which were due to intracranial bleeding associated with celecoxib, ciprofloxacin, and fluoxetine/diazepam coadministration.<sup>54-56</sup> Only 2 of all 34 reports were level I, describing inhibition involving mesalamine and trazodone.<sup>32,34</sup> Several herbal drugs, foods rich in vitamin K, and carbamazepine were reported to decrease warfarin's effect as were other anti-infective agents, including griseofulvin, rifampin, and penicillinase-resistant penicillins, such as nafcillin, dicloxacillin, and cloxacillin.

There were 3 drugs—terbinafine, ritonavir, and influenza vaccine—for which conflicting evidence of an interaction with warfarin was presented.<sup>57-63</sup> A cumulative

summary, combining evaluations from our original review<sup>6</sup> with those of the update is presented in **Table 2**. Although few interactions met level I causation requirements, the recurrent reports on non-steroidal anti-inflammatory drugs (NSAIDs),<sup>230</sup> antibiotics (particularly macrolides—azithromycin,<sup>124</sup> erythromycin,<sup>11</sup> and clarithromycin<sup>126</sup>), azoles (fluconazole<sup>231</sup> and miconazole<sup>25</sup>), amoxicillin, and quinolones (ciprofloxacin<sup>16</sup> and levofloxacin<sup>139</sup>) continue. New alerts regarding the potential for major bleeding when warfarin is taken with cyclooxygenase-2 (COX-2) selective NSAIDs<sup>9,10,55,232</sup> or herbal drugs are raised.<sup>127,233</sup> **Table 3** presents a summary of all clinically significant potentiation and inhibition interactions with warfarin, based on drug family and level of causation.

The most commonly cited mechanisms for interactions with warfarin involved stereoselective clearance due to S-enantiomer (ritonavir and cotrimoxazole) or non-stereoselective clearance (simvastatin and terbinafine) or the vitamin K pathway (green tea). However, most of the interactions reported have no documented mechanism.

## COMMENT

This updated review indicates that the number of reports of interactions between warfarin and drugs or foods is increasing, reaffirming both the anticoagulant's widespread use and its use with concomitant medications. Although the true mechanisms of drug interactions almost always remain unknown, there are several pharmacokinetic and pharmacodynamic factors that could influence warfarin's effect. Cholestyramine is thought to reduce the gastrointestinal absorption of warfarin.<sup>97,234</sup> The more potent warfarin S-isomer is metabolized by cytochrome P-450 (CYP) 2C9. Many of the drugs identified as potentiating warfarin's effect are known inhibitors of CYP 2C9, including amiodarone, fluconazole, fluvastatin, fluvoxamine, isoniazid, lovastatin, phenylbutazone, and sertraline.<sup>235</sup> Rifampin and secobarbital are both known inducers of CYP 2C9.<sup>93,102</sup>

The R-isomer of warfarin is metabolized by CYP 1A2 and CYP 3A4, and quinolones<sup>16,139</sup> inhibit CYP 1A2, and macrolides<sup>11,124,126</sup> inhibit CYP 3A4. The azoles (several reports involving metronidazole, fluconazole, trimethoprim-sulfamethoxazole, miconazole, and voriconazole<sup>25,28,79,81-83,236</sup>) are also considered to inhibit CYP 1A2 or CYP 3A4. The pharmacodynamics of warfarin may be influenced by medications that affect either vitamin K or the coagulation factors.<sup>237</sup> Sudden changes in dietary sources of vitamin K such as leafy greens or a supplemented diet followed by a change in warfarin's effect are relatively easy to understand.<sup>106,238-240</sup> However, for several drugs, including cephalosporins, levothyroxine, and clofibrate, their supposed pharmacodynamic interactions with warfarin are very poorly understood.<sup>76,214,241</sup>

Although understanding a drug's pharmacology helps predict its potential for interaction with warfarin, the translation of these predictions into clinical reality is far from certain. We also found no evidence that specific factors might identify patient subgroups most at risk of pharmacokinetic drug interactions. Regular monitoring of INR remains the best protection against major harm due to these pharmacokinetic and pharmacodynamic interactions.

The most difficult groups of drugs to deal with are those that potentiate bleeding on their own. The risk of bleeding is then greater when taken with warfarin, and INR monitoring is of no help. This is an issue with other anticoagulants (such as heparin), antiplatelet drugs (eg, acetylsalicylic acid, clopidogrel, dipyridamole, sulfinpyrazole, and ticlopidine) and all NSAIDs including COX-2 selective NSAIDs. All of these drugs should be avoided in combination with warfarin unless proven to provide benefit that outweighs the risk of bleeding—for example, for artificial heart valves.<sup>237</sup> Contrary to the early theories of safety of COX-2 selective NSAIDs, we do not consider them safe in combination with warfarin. Both celecoxib (10 cases moderate<sup>9,232</sup> to major<sup>9,10</sup>) and rofecoxib (2 cases moderate<sup>9</sup>) are reported to potentiate anticoagulation. Acetami-

nophen, which is the analgesic of choice for patients using warfarin, has case reports<sup>17,242</sup> as well as a case-control study<sup>243</sup> suggesting moderate potentiation (perhaps based on mild factor VII depletion<sup>17,243</sup>), although findings from an RCT in healthy volunteers were negative.<sup>244</sup>

The paradox noted in our original review continues, in that higher-quality studies describe minor or no interaction, while clinically important potentiation or inhibition interactions all originate from poor-quality reports. The overall quality of the interaction literature remains extremely poor, precluding definitive recommendations regarding the safe coadministration or avoidance of specific drugs and foods in users of warfarin. Case reports may be alarming, but their rarity and the lack of a control group, a denominator of use, or often even basic descriptive details makes it impossible to gauge their true accuracy or rate of harm. Small RCTs of new drugs given with warfarin are increasingly common as a result of demands of regulators. These studies, which are invariably carried out with healthy young male volunteers, are too small to provide any assurance of lack of interaction and are likely not generalizable to the usual warfarin consumer—an elderly person with active medical conditions using several other medications. Only 5 of 34 RCTs evaluated in this review involved sample sizes from 24 to 43 patients.<sup>12-16</sup> Poor-quality literature is not merely an aggravation to review. Twenty of the interaction reports received a level IV causation rating, implying that the interaction was highly improbable based on the lack of fulfillment of basic causation criteria.<sup>56,213-229</sup> The publication of such reports is potentially harmful itself because it may generate unwarranted concern and erroneously influence prescribing. We were surprised to find no analyses of linked, large administrative databases examining drug interactions with warfarin.

This review has several limitations. Our literature search did not solicit all unpublished adverse interactions reported to drug manufacturers or governments. However, both

**Table 2. Drug and Food Interactions With Warfarin by Level of Causation and Direction of Interaction\***

| Level of Causation   | Potentialiation   | Inhibition  | No Effect   |  |
|--|---|---|---|--|
| I (Highly probable)  | <b>Acetaminophen</b> <sup>17</sup>                                | Barbituates <sup>93,94</sup>                                | Alcohol <sup>†109,110</sup>                                 |  |
|  | Alcohol (if concomitant liver disease) <sup>†64</sup>             | Carbamazepine <sup>†95</sup>                                | Anastrozole <sup>‡ (N = 16)</sup> <sup>35</sup>             |  |
|  | Amiodarone <sup>†65-67</sup>                                      | Chlordiazepoxide <sup>†96</sup>                             | Antacids <sup>†97</sup>                                     |  |
|  | Anabolic steroids <sup>†68,69</sup>                               | Cholestyramine <sup>†97,98</sup>                            | Argatroban <sup>‡36</sup>                                   |  |
|  | <b>Boldo-fenugreek</b> <sup>18</sup>                              | Etodolac <sup>‡ (N = 18)</sup> <sup>30</sup>                | Atenolol <sup>†89</sup>                                     |  |
|  | Cimetidine <sup>†70-75</sup>                                      | Griseofulvin <sup>†99,100</sup>                             | Bumetadine <sup>†111</sup>                                  |  |
|  | Ciprofloxacin <sup>‡ (n = 34)</sup> <sup>16</sup>                 | <b>Mercaptopurine</b> <sup>51</sup>                         | Cilostazol <sup>‡ (N = 15)</sup> <sup>37</sup>              |  |
|  | <i>Citalopram</i> <sup>‡ (n = 12)</sup> <sup>19</sup>             | <b>Mesalamine</b> <sup>32</sup>                             | Clopidogrel <sup>‡ (N = 43)</sup> <sup>14</sup>             |  |
|  | Clofibrate <sup>†76</sup>   | Nafcillin <sup>†101</sup>                                   | Diflunisal <sup>†112</sup>                                  |  |
|  | Cotrimoxazole <sup>†77</sup>                                      | <b>Ribavirin</b> <sup>33</sup>                              | Donepezil hydrochloride <sup>‡ (N = 12)</sup> <sup>38</sup> |  |
|  | Diltiazem <sup>‡ (n = 20)</sup> <sup>20</sup>                     | Rifampin <sup>†102,103</sup>                                | Enoxacin <sup>†113</sup>                                    |  |
|  | <i>Entacapone</i> <sup>‡ (n = 12)</sup> <sup>21</sup>             | Sucralfate <sup>†104,105</sup>                              | Eprosartan <sup>‡ (N = 18)</sup> <sup>39</sup>              |  |
|  | Erythromycin <sup>†78</sup>                                       | <b>Trazodone</b> <sup>34</sup>                              | Famotidine <sup>†114</sup>                                  |  |
|  | <b>Fenofibrate</b> <sup>22</sup>                                  | High vitamin K content                                      | Felodipine <sup>†115</sup>                                  |  |
|  | <b>Fish oil</b> <sup>23</sup>                                     | foods/enteral feeds <sup>†106,107</sup>                     | Fluoxetine <sup>†116</sup>                                  |  |
|  | Fluconazole <sup>†79</sup>  | Large amounts of avocado <sup>†108</sup>                    | Fondaparinux <sup>‡ (N = 12)</sup> <sup>40</sup>            |  |
|  | Isoniazid <sup>†80</sup>  |   | Gemifloxacin <sup>‡ (n = 35)</sup> <sup>41</sup>            |  |
|  | <b>Mango</b> <sup>24</sup>  |   | Ketorolac <sup>†117</sup>                                   |  |
|  | Metronidazole <sup>†81</sup>                                      |   | Levetiracetam <sup>‡ (N = 26)</sup> <sup>42</sup>           |  |
|  | Miconazole oral gel <sup>†82</sup>                                |   | Losartan <sup>‡ (N = 9)</sup> <sup>43</sup>                 |  |
|  | <b>Miconazole vaginal suppositories</b> <sup>25</sup>             |   | Meloxicam <sup>‡ (N = 13)</sup> <sup>44</sup>               |  |
|  | Omeprazole <sup>†83</sup>   |   | Metoprolol <sup>†89</sup>                                   |  |
|  | Phenylbutazone <sup>†84,85</sup>                                  |   | Metrifonate <sup>‡ (N = 14)</sup> <sup>45</sup>             |  |
|  | Piroxicam <sup>†86</sup>  |   | Miglitol <sup>‡ (N = 19)</sup> <sup>46</sup>                |  |
|  | Propafenone <sup>†87</sup>  |   | Modafinil <sup>‡ (N = 28)</sup> <sup>47</sup>               |  |
|  | Propranolol <sup>†88,89</sup>                                     |   | Moexipril <sup>‡ (N = 10)</sup> <sup>48</sup>               |  |
|  | <b>Quilinggao</b> <sup>26</sup>                                   |   | Montelukast <sup>‡ (N = 12)</sup> <sup>49</sup>             |  |
|  | <i>Sertraline</i> <sup>‡ (n = 12)</sup> <sup>27</sup>             |   | Moricizine <sup>†118</sup>                                  |  |
|  | Sulfinpyrazone (biphasic with later inhibition) <sup>†90-92</sup> |   | Naproxen <sup>†119</sup>                                    |  |
|  | <i>Voriconazole</i> <sup>‡ (n = 17)</sup> <sup>28</sup>           |   | Nateglinide <sup>‡ (N = 12)</sup> <sup>50</sup>             |  |
|  | <i>Zileuton</i> <sup>‡ (n = 24)</sup> <sup>29</sup>               |   | Nefazodone <sup>‡ (N = 17)</sup> <sup>51</sup>              |  |
|  |   |   | Nizatidine <sup>†120</sup>                                  |  |
|  |   |   | Olestra <sup>‡ (N = 36)</sup> <sup>12</sup>                 |  |
|  |   |   | Pantoprazole <sup>‡ (N = 26)</sup> <sup>52</sup>            |  |
|  |   |   | Psyllium <sup>†97</sup>                                     |  |
|  |   |   | Ranitidine <sup>†71,121</sup>                               |  |
|  |   |   | Sevelamer hydrochloride <sup>‡ (N = 14)</sup> <sup>53</sup> |  |
|  |   |   | Vitamin E <sup>‡ (N = 25)</sup> <sup>13</sup>               |  |
|  | II (Probable)   | Acetylsalicylic acid <sup>†122</sup>                        | <b>Azathioprine</b> <sup>156</sup>                          | Atorvastatin <sup>167</sup>                                    |
|  |   | <b>Amoxicillin/clavulanate</b> <sup>123</sup>               | <b>Bosentan</b> <sup>157</sup>                              | Cilomilast <sup>‡ (N = 36)</sup> <sup>168</sup>                |
|  |   | <b>Azithromycin</b> <sup>124</sup>                          | Candesartan cilexetil <sup>†158</sup>                       | Coenzyme Q10/ginkgo biloba <sup>‡ (N = 24)</sup> <sup>15</sup> |
| <b>Celecoxib</b> <sup>9</sup>                              |   | <b>Chelation therapy</b> <sup>159</sup>                     | Colesevelam hydrochloride <sup>169</sup>                    |  |
| Choral hydrate <sup>†125</sup>                             |   | <b>Dicloxacillin</b> <sup>†160,161</sup>                    | Ibuprofen <sup>†170</sup>                                   |  |
| <b>Clarithromycin</b> <sup>126</sup>                       |   | <b>Ginseng</b> <sup>162</sup>                               | Influenza vaccine <sup>†62,63</sup>                         |  |
| <b>Danshen</b> <sup>127</sup>                              |   | <i>Influenza vaccine</i> <sup>61</sup>                      | Ketoconazole <sup>†171</sup>                                |  |
| Dextropropoxyphene <sup>†128</sup>                         |   | Multivitamin supplement containing vitamin K <sup>163</sup> | Ketoprofen <sup>†172</sup>                                  |  |
| Disulfiram <sup>†129</sup>                                 |   | <i>Raloxifene hydrochloride</i> <sup>164</sup>              | Levosimendan <sup>173</sup>                                 |  |
| <b>Dong quai</b> <sup>130</sup>                            |   | <b>Ritonavir</b> <sup>165</sup>                             |   |  |
| <b>Fluorouracil</b> <sup>131</sup>                         |   | <i>Soy milk</i> <sup>166</sup>                              |   |  |
| <b>Fluvastatin</b> <sup>132</sup>                          |   |   |   |  |
| <b>Fluvoxamine</b> <sup>133</sup>                          |   |   |   |  |
| <b>Gemcitabine</b> <sup>134</sup>                          |   |   |   |  |
| <b>Grapefruit juice</b> <sup>135</sup>                     |   |   |   |  |
| <b>Interferon</b> <sup>136</sup>                           |   |   |   |  |
| Itraconazole <sup>†137</sup>                               |   |   |   |  |
| <b>Levamisole/fluorouracil</b> <sup>138</sup>              |   |   |   |  |
| <b>Levofloxacin</b> <sup>139</sup>                         |   |   |   |  |
| <b>Lycium barbarum L</b> <sup>140</sup>                    |   |   |   |  |
| <b>PC-SPES</b> <sup>141</sup>                              |   |   |   |  |
| <b>Paclitaxel</b> <sup>142</sup>                           |   |   |   |  |
| <b>Paracetamol</b> <sup>143</sup>                          |   |   |   |  |
| Phenytoin (biphasic with later inhibition) <sup>†144</sup> |   |   |   |  |
| Quinidine <sup>†145</sup>                                  |   |   |   |  |
| <b>Ritonavir</b> <sup>146</sup>                            |   |   |   |  |
| <b>Ropinirole</b> <sup>146</sup>                           |   |   |   |  |
| <i>Simvastatin</i> <sup>†147,148</sup>                     |   |   |   |  |
| Tamoxifen <sup>†149</sup>                                  |   |   |   |  |
| Tetracycline <sup>†150,151</sup>                           |   |   |   |  |
| <b>Tolterodine</b> <sup>152</sup>                          |   |   |   |  |
| <b>Tramadol</b> <sup>153,154</sup>                         |   |   |   |  |
| <b>Troglitazone</b> <sup>155</sup>                         |   |   |   |  |

continued

**Table 2. Drug and Food Interactions With Warfarin by Level of Causation and Direction of Interaction\* (cont)**

| Level of Causation     | Potentialiation  | Inhibition   | No Effect  |
|------------------------|--|--|--|
| III (Possible)         | <p><b>Acarbose</b><sup>174</sup><br/> <b>Amiodarone-induced toxicosis</b><sup>175</sup><br/> <i>Amoxicillin</i><sup>1</sup><br/> <b>Amoxicillin/tranexamic rinse</b><sup>176</sup><br/> <b>CMF (cyclophosphamide/methotrexate/fluorouracil)</b><sup>177</sup><br/> <b>Chloramphenicol</b><sup>178</sup><br/>           Cranberry juice<sup>179</sup><br/> <i>Curbicin</i><sup>180</sup><br/> <b>Danazol</b><sup>181</sup><br/> <b>Danshen/methyl salicylate</b><sup>82</sup><br/>           Disopyramide†<sup>183,184</sup><br/> <b>Felbamate</b><sup>185</sup><br/> <b>Gatifloxacin</b><sup>186</sup><br/> <b>Gemfibrozil</b><sup>187</sup><br/> <b>Indomethacin</b><sup>188</sup><br/>           Ifosphamide†<sup>189</sup><br/>           Lovastatin†<sup>190</sup><br/>           Leflunomide<sup>191</sup><br/>           Metolazone†<sup>192</sup><br/> <b>Miconazole topical gel</b><sup>193</sup><br/>           Nalidixic acid†<sup>194</sup><br/>           Norfloxacin†<sup>195</sup><br/> <b>Ofloxacin</b>†<sup>196,197</sup><br/> <b>Orlistat</b><sup>198</sup><br/>           Propoxyphene†<sup>128</sup><br/> <b>Rofecoxib</b><sup>9</sup><br/>           Topical salicylates†<sup>199,200</sup><br/> <b>Saquinavi</b>†<sup>201</sup><br/>           Sulindac†<sup>202,203</sup><br/> <b>Terbinafine</b><sup>59</sup><br/>           Ticlopidine<sup>204</sup><br/>           Tolmetin†<sup>205</sup><br/> <b>Trastuzumab</b><sup>206</sup></p> | <p>Cyclosporine†<sup>207</sup><br/>           Etretnate†<sup>208</sup><br/> <b>Sulfasalazine</b><sup>209</sup><br/> <b>Sushi containing seaweed</b><sup>210</sup><br/> <i>Telmisartan</i><sup>211</sup><br/> <b>Terbinafine</b><sup>58</sup><br/> <b>Ubidecarenone</b><sup>212</sup></p> |  |
| IV (Highly improbable) | <p><b>Bezafibrate</b><sup>213</sup><br/>           Cefamandole†<sup>214</sup><br/>           Cefazolin†<sup>214</sup><br/> <b>Etoposide/carboplatin</b><sup>215</sup><br/> <b>Fluoxetine/diazepam</b><sup>56</sup><br/>           Heparin†<sup>216</sup><br/> <b>Levamisole</b><sup>217</sup><br/> <b>Evonorgestrel</b><sup>218</sup><br/> <b>Methylprednisolone</b><sup>219</sup><br/> <b>Nabumetone</b><sup>220</sup><br/> <b>Quetiapine</b><sup>221</sup><br/>           Sulfisoxazole†<sup>222</sup></p>   | <p><b>Cloxacillin</b><sup>223</sup><br/> <b>Furosemide</b><sup>224</sup><br/> <b>Green tea</b><sup>225</sup><br/> <i>Nafcillin/dicloxacillin</i><sup>226</sup><br/> <b>Propofol</b><sup>227</sup><br/> <b>Teicoplanin</b><sup>228</sup></p>  | <p>Tobacco†<sup>229</sup><br/>           Vancomycin†<sup>214</sup></p> |

\*Interaction key: major interaction (***bold/italics***); moderate interaction (***bold***); minor interaction (*italics*); nonclinical interaction (regular).

†Data from 1994 review.<sup>6</sup>

‡Drugs and foods for which evidence is based on fair- to good-quality randomized controlled trials; numbers in parentheses indicate number of subjects in trial.

Health Canada's Canadian Adverse Drug Reaction Monitoring Program and Food and Drug Administration's MedWatch were solicited for cases. We also were unable to review all non-English publications. The handling of conflicting evidence, while sensible, could have led to a mistaken conclusion. Others may not agree with our multidimensional, hierarchical evaluation methods.

In the extreme, no drug can be deemed "safe" based on our summary chart because the absence of

proof of a severe interaction does not mean proof of absence. Idiosyncratic reactions can always be expected. We therefore continue to recommend careful monitoring of warfarin therapy at the time of introduction of any new medication, herbal product, or food. Herbal products are particularly problematic given the lack of quality control on their contents and the failure of clinicians to ask about their use.<sup>245,246</sup>

How can clinicians use this information? To prescribe safely, there

are 3 choices: one is to never prescribe or allow another medicine to be given with warfarin. This is clearly impractical for most patients requiring warfarin. The second is to use an electronic medical record or prescribing system that will evaluate interactions among the patient's entire profile of therapies.<sup>247,248</sup> Because these systems are not available to most physicians and are frequently incomplete and sometimes inaccurate, a third approach is required. The third option is to group the majority of offending interacting drugs

**Table 3. Clinically Significant Interactions With Warfarin by Level of Causation and Drug Group**

| Level of Causation     | Anti-infectives   | Cardiovascular Drugs   | Analgesics, Anti-inflammatories and Immunologics   |  | CNS Drugs   |
|------------------------|---|--|--|--|---|
|                        |   |  |  |  |   |
|                        |   | <b>Potential</b>   |  |  |   |
| I (Highly probable)    | Ciprofloxacin <sup>16</sup><br>Cotrimoxazole <sup>77</sup><br>Erythromycin <sup>78</sup><br>Fluconazole <sup>79</sup><br>Isoniazid (600 mg/d) <sup>80</sup><br>Metronidazole <sup>81</sup><br>Miconazole oral gel <sup>82</sup><br>Miconazole vaginal suppositories <sup>25</sup><br>Voriconazole <sup>28</sup>                         | Amiodarone <sup>65-67</sup><br>Clofibrate <sup>76</sup><br>Diltiazem <sup>20</sup><br>Fenofibrate <sup>22</sup><br>Propafenone <sup>87</sup><br>Propranolol <sup>88</sup><br>Sulfapyrazole (biphasic with later inhibition) <sup>90-92</sup> | Phenylbutazone <sup>84,85</sup><br>Piroxicam <sup>86</sup>   |  | Alcohol (if concomitant liver disease) <sup>64</sup><br>Citalopram <sup>19</sup><br>Entacapone <sup>21</sup><br>Sertraline <sup>27</sup>              |
| II (Probable)          | Amoxicillin/clavulanate <sup>123</sup><br>Azithromycin <sup>124</sup><br>Clarithromycin <sup>126</sup><br>Itraconazole <sup>137</sup><br>Levofloxacin <sup>139</sup><br>Ritonavir <sup>60</sup><br>Tetracycline <sup>150,151</sup>  | Acetylsalicylic acid <sup>122</sup><br>Fluvastatin <sup>132</sup><br>Quinidine <sup>145</sup><br>Ropinirole <sup>146</sup><br>Simvastatin <sup>147</sup>   | Acetaminophen <sup>17</sup><br>Acetylsalicylic acid <sup>122</sup><br>Celecoxib <sup>9</sup><br>Dextropropoxyphene <sup>128</sup><br>Interferon <sup>136</sup><br>Tramadol <sup>153</sup>  |  | Disulfiram <sup>129</sup><br>Choral hydrate <sup>125</sup><br>Fluvoxamine <sup>133</sup><br>Phenytoin (biphasic with later inhibition) <sup>144</sup> |
| III (Possible)         | Amoxicillin <sup>11</sup><br>Amoxicillin/tranexamic rinse <sup>176</sup><br>Chloramphenicol <sup>178</sup><br>Gatifloxacin <sup>186</sup><br>Miconazole topical gel <sup>193</sup><br>Nalidixic acid <sup>194</sup><br>Norfloxacin <sup>195</sup><br>Ofloxacin <sup>197</sup><br>Saquinavir <sup>201</sup><br>Terbinafine <sup>59</sup> | Amiodarone-induced toxicosis <sup>175</sup><br>Disopyramide <sup>183,184</sup><br>Gemfibrozil <sup>187</sup><br>Metolazone <sup>192</sup>  | Celecoxib <sup>9</sup><br>Indomethacin <sup>188</sup><br>Leflunomide <sup>191</sup><br>Propoxyphene <sup>128</sup><br>Rofecoxib <sup>9</sup><br>Sulindac <sup>202</sup><br>Tolmetin <sup>205</sup><br>Topical salicylates <sup>199,200</sup> |  | Felbamate <sup>185</sup>  |
| IV (Highly improbable) | Cefamandole <sup>214</sup><br>Cefazolin <sup>214</sup><br>Sulfisoxazole <sup>222</sup>  | Bezafibrate <sup>213</sup><br>Heparin <sup>216</sup>   | Levamisole <sup>217</sup><br>Methylprednisolone <sup>219</sup><br>Nabumetone <sup>220</sup>  |  | Fluoxetine/diazepam <sup>56</sup><br>Quetiapine <sup>221</sup>  |
|                        |   | <b>Inhibition</b>  |  |  |   |
| I (Highly probable)    | Griseofulvin <sup>99,100</sup><br>Nafcillin <sup>101</sup><br>Ribavirin <sup>33</sup><br>Rifampin <sup>102,103</sup>  | Cholestyramine <sup>97,98</sup>  | Mesalamine <sup>32</sup>   |  | Barbiturates <sup>93,94</sup><br>Carbamazepine <sup>95</sup>  |
| II (Probable)          | Dicloxacillin <sup>160,161</sup><br>Ritonavir <sup>165</sup>  | Bosentan <sup>157</sup>  | Azathioprine <sup>156</sup>  |  | Chlordiazepoxide <sup>96</sup>  |
| III (Possible)         | Terbinafine <sup>58</sup>   | Telmisartan <sup>211</sup>   | Sulfasalazine <sup>209</sup>   |  |   |
| IV (Highly improbable) | Cloxacillin <sup>223</sup><br>Nafcillin/dicloxacillin <sup>226</sup><br>Teicoplanin <sup>228</sup>  | Furosemide <sup>224</sup>  |  |  | Propofol <sup>227</sup>   |

(continued)

into easier-to-remember families or therapeutic groups, as we have done in Table 3. We recommend to exercise caution when adding any antibiotic to warfarin therapy, especially for macrolides, quinolones, and “azoles.” Many common cardiovascular drugs, including statins, fibrates, heparin, aspirin, and amiodarone, are problematic. Also, NSAIDs, including COX-2 selective NSAIDs, should be avoided, as should omeprazole, alcohol, choral hydrate, anabolic steroids, and a wide variety of, if not all, herbal supplements. New oral anticoagu-

lants may soon be available but have not demonstrated superior long-term efficacy, safety, or drug interaction profile compared with warfarin.

### CONCLUSIONS

In summary, there is an abundance of medications and foods for which an adverse interaction with warfarin, generally potentiation of warfarin's effect, has been reported. While the drug interaction literature is generally of poor quality, rela-

tively consistent reporting of interactions between warfarin and certain commonly used drugs and drug families (mainly anti-infective agents, lipid-lowering drugs, NSAIDs including COX-2 selective NSAIDs, selective serotonin reuptake inhibitors, amiodarone, omeprazole, fluorouracil, and cimetidine) is cause for concern. In patients who are starting therapy with one of these medicines, consideration should be given to using an alternative medication with less potential for warfarin interactions (eg, rabeprazole instead of omeprazole and acetaminophen in-

**Table 3. Clinically Significant Interactions With Warfarin by Level of Causation and Drug Group (cont)**

| Level of Causation     | GI Drugs and Food  | Herbal Supplements   | Other Drugs  |
|------------------------|--|--|--|
| <b>Potentiation</b>    |  |  |  |
| I (Highly probable)    | Cimetidine <sup>70-75</sup><br>Fish oil <sup>23</sup><br>Mango <sup>24</sup><br>Omeprazole <sup>83</sup> | Boldo-fenugreek <sup>18</sup><br>Quilinggao <sup>26</sup>  | Anabolic steroids <sup>88,69</sup><br>Zileuton <sup>29</sup>   |
| II (Probable)          | Grapefruit juice <sup>135</sup>  | Danshen <sup>127</sup><br>Dong quai <sup>130</sup><br>Lycium barbarum L <sup>140</sup><br>PC-SPES <sup>141</sup> | Fluorouracil <sup>131</sup><br>Gemcitabine <sup>134</sup><br>Levamisole/fluorouracil <sup>138</sup><br>Paclitaxel <sup>142</sup><br>Tamoxifen <sup>149</sup><br>Tolterodine <sup>152</sup>                     |
| III (Possible)         | Cranberry juice <sup>179</sup><br>Orlistat <sup>198</sup>  | Danshen/methyl salicylate <sup>182</sup>   | Acarbose <sup>174</sup><br>CMF (cyclophosphamide/<br>methotrexate/fluorouracil) <sup>177</sup><br>Curbicin <sup>180</sup><br>Danazol <sup>181</sup><br>Ifosfamide <sup>189</sup><br>Trastuzumab <sup>206</sup> |
| IV (Highly improbable) |  |  | Etoposide/carboplatin <sup>215</sup><br>Levonorgestrel <sup>218</sup>  |
| <b>Inhibition</b>      |  |  |  |
| I (Highly probable)    | High vitamin K content foods/enteral feeds <sup>106,107</sup><br>Avocado (large amounts) <sup>108</sup>  |  | Mercaptopurine <sup>31</sup>   |
| II (Probable)          | Soy milk <sup>166</sup><br>Sucralfate <sup>104,105</sup>   | Ginseng <sup>162</sup>   | Chelation therapy <sup>159</sup><br>Influenza vaccine <sup>61</sup><br>Multivitamin supplement <sup>163</sup><br>Raloxifene hydrochloride <sup>164</sup>   |
| III (Possible)         | Sushi containing seaweed <sup>210</sup>  |  | Cyclosporine <sup>207</sup><br>Etretinate <sup>208</sup><br>Ubidecarenone <sup>212</sup>   |
| IV (Highly improbable) |  | Green tea <sup>225</sup>   |  |

Abbreviations: CNS, central nervous system; GI, gastrointestinal.

stead of NSAIDs). More frequent INR testing during the 2 weeks of the onset or discontinuation of treatment with other medications is advisable. Finally, we recommend the use of more rigorous methods to examine warfarin interactions in patients (eg, RCTs, N of 1 crossover studies, or large health database analyses).

Accepted for Publication: December 21, 2004.

Correspondence: Anne M. Holbrook, MD, PharmD, MSc, FRCPC, Division of Clinical Pharmacology, McMaster University, c/o Centre for Evaluation of Medicines, 105 Main St E, Level P1, Hamilton, Ontario, Canada L8N 1G6 (holbrook@mcmaster.ca).

## REFERENCES

- Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE. Antithrombotic therapy in atrial fibrillation. *Chest*. 2001;119(suppl):194S-206S.
- Stein PD, Alpert JS, Bussey HI, Dalen JE, Turpie AGG. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves [published correction appears in *Chest*. 2001;120:1044]. *Chest*. 2001;119(suppl):220S-227S.
- Hyers TMAG, Hull RD, Morris TA, Samama M, Tapson V, Weg JG. Antithrombotic therapy for venous thromboembolic disease. *Chest*. 2001;119(suppl):176S-193S.
- Cairns JA, Theroux P, Lewis HD Jr, Ezekowitz M, Meade TW. Antithrombotic agents in coronary artery disease [published correction appears in *Chest*. 2001;120:1427]. *Chest*. 2001;119(suppl):228S-252S.
- Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action clinical effectiveness and optimal therapeutic range. *Chest*. 2001;119(suppl 1):8S-21S.
- Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and food. *Ann Intern Med*. 1994;121:676-683.
- Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. *Am J Med*. 1998;105:91-99.
- Fleiss JL. *Statistical Methods for Rates and Proportions*. New York, NY: John Wiley & Sons; 1981:212-225.
- Stading JA, Skrabal MZ, Faulkner MA. Seven cases of interaction between warfarin and cyclooxygenase-2 inhibitors. *Am J Health Syst Pharm*. 2001;58:2076-2080.
- Mersfelder TL, Stewart LR. Warfarin and celecoxib interaction. *Ann Pharmacother*. 2000;34:325-327.
- Wood GD, Deeb T. Warfarin: dangers with antibiotics. *Dent Update*. 1993;20:350-353.
- Beckey NP, Korman LB, Parra D. Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy. *Pharmacotherapy*. 1999;19:1075-1079.
- Kim JM, White RH. Effect of vitamin E on the anticoagulant response to warfarin. *Am J Cardiol*. 1996;77:545-546.
- Lidell C, Svedberg LE, Lindell P, Bandh S, Job B, Wallentin L. Clopidogrel and warfarin: absence of interaction in patients receiving long-term anticoagulant therapy for non-valvular atrial fibrillation. *Thromb Haemost*. 2003;89:842-846.
- Engelsen J, Nielsen JD, Hansen KE. Effect of coenzyme Q10 and ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment: a randomized double-blind, placebo-controlled cross-over trial. *Ugeskr Laeger*. 2003;165:1868-1871.
- Israel DS, Stotka J, Rock W, et al. Effect of ciprofloxacin on the pharmacokinetics and pharmacodynamics of warfarin. *Clin Infect Dis*. 1996;22:251-256.



17. Gebauer MG, Nyfort-Handsen K, Henschke PJ, Gallus AS. Warfarin and acetaminophen interaction. *Pharmacotherapy*. 2003;23:109-112.
18. Lambert J, Cormier J. Potential interaction between warfarin and boldo-fenugreek. *Pharmacotherapy*. 2001;21:509-512.
19. Priskorn M, Sidhu JS, Larsen F, Davis JD, Khan AZ, Rolan PE. Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin. *Br J Clin Pharmacol*. 1997;44:199-202.
20. Stoysich AM, Lucas BD, Mohiuddin SM, Hilleman DE. Further elucidation of pharmacokinetic interaction between diltiazem and warfarin. *Int J Clin Pharmacol Ther*. 1996;34:56-60.
21. Dingemans J, Meyerhoff C, Schadrack J. Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin. *Br J Clin Pharmacol*. 2002;53:485-491.
22. Ascah KJ, Rock GA, Wells PS. Interaction between fenofibrate and warfarin. *Ann Pharmacother*. 1998;32:765-768.
23. Buckley MS, Goff AD, Knapp WE. Fish oil interaction with warfarin. *Ann Pharmacother*. 2004;38:50-53.
24. Monterrey-Rodriguez J. Interaction between warfarin and mango fruit [letter]. *Ann Pharmacother*. 2002;36:940-941.
25. Thirion DJ, Zanetti LA. Potentiation of warfarin's hypoprothrombinemic effect with miconazole vaginal suppositories. *Pharmacotherapy*. 2000;20:98-99.
26. Wong ALN, Chan TYK. Interaction between warfarin and the herbal product quilinggao. *Ann Pharmacother*. 2003;37:836-838.
27. Apseloff G, Wilner KD, Gerber N, Tremaine LM. Effect of sertraline on protein binding of warfarin. *Clin Pharmacokinet*. 1997;32(suppl 1):37-42.
28. Purkins L, Wood N, Kleinermans D, Nichols D. Voriconazole potentiates warfarin-induced prothrombin time prolongation. *Br J Clin Pharmacol*. 2003;56:24-29.
29. Awni WM, Hussein Z, Granneman GR, Patterson KJ, Dube LM, Cavanaugh JH. Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans. *Clin Pharmacokinet*. 1995;29(suppl 2):67-76.
30. Ermer JC, Hicks DR, Wheeler SC, Kraml M, Jusko WJ. Concomitant etodolac affects neither the unbound clearance nor the pharmacologic effect of warfarin. *Clin Pharmacol Ther*. 1994;55:305-316.
31. Martin LA, Mehta SD. Diminished anticoagulant effects of warfarin with concomitant mercaptopurine therapy. *Pharmacotherapy*. 2003;23:260-264.
32. Marinella MA. Mesalamine and warfarin therapy resulting in decreased warfarin effect. *Ann Pharmacother*. 1998;32:841-842.
33. Schulman S. Inhibition of warfarin activity by ribavirin. *Ann Pharmacother*. 2002;36:72-74.
34. Small NL, Giamonna KA. Interaction between warfarin and trazodone. *Ann Pharmacother*. 2000;34:734-736.
35. Yates RA, Wong J, Seiberling M, Merz M, Marz W, Nauck M. The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers. *Br J Clin Pharmacol*. 2001;51:429-435.
36. Brown PM, Hursting MJ. Lack of pharmacokinetic interactions between argatroban and warfarin. *Am J Health Syst Pharm*. 2002;59:2078-2083.
37. Mallikarjun S, Bramer SL. Effect of cilostazol on the pharmacokinetics and pharmacodynamics of warfarin. *Clin Pharmacokinet*. 1999;37(suppl 2):79-86.
38. Tiseo PJ, Foley K, Friedhoff LT. The effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin. *Br J Clin Pharmacol*. 1998;46(suppl 1):45-50.
39. Kazierad DJ, Martin DE, Ilson B, et al. Eprosartan does not affect the pharmacodynamics of warfarin. *J Clin Pharmacol*. 1998;38:649-653.
40. Faaij RA, Burggraaf J, Schoemaker RC, van Amsterdam RGM, Cohen AF. Absence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin. *Br J Clin Pharmacol*. 2002;54:304-308.
41. Davy M, Bird N, Rost KL, Fuder H. Lack of effect of gemifloxacin on the steady-state pharmacodynamics of warfarin in healthy volunteers. *Chemotherapy*. 1999;45:491-495.
42. Ragueneau-Majlessi I, Levy RH, Meyerhoff C. Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin. *Epilepsy Res*. 2001;47:55-63.
43. Kong AN, Tomasko L, Waldman SA, et al. Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin. *J Clin Pharmacol*. 1995;35:1008-1015.
44. Turck D, Su CA, Heinzl G, Busch U, Bluhmki E, Hoffmann J. Lack of interaction between meloxicam and warfarin in healthy volunteers. *Eur J Clin Pharmacol*. 1997;51:421-425.
45. Heinig R, Kitchin N, Rolan P. Disposition of a single dose of warfarin in healthy individuals after pretreatment with metrifonate. *Clin Drug Invest*. 1999;18:151-159.
46. Schall R, Muller FO, Hundt HK, Duursema L, Groenewoud G, Middle MV. Study of the effect of miglitol on the pharmacokinetics and pharmacodynamics of warfarin in healthy males. *Arzneimittelforschung*. 1996;46:41-46.
47. Robertson P Jr, Hellriegel ET, Arora S, Nelson M. Effect of modafinil at steady state on the single-dose pharmacokinetic profile of warfarin in healthy volunteers. *J Clin Pharmacol*. 2002;42:205-214.
48. Van Hecken A, Verbesselt R, Depre M, et al. Moexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin. *Eur J Clin Pharmacol*. 1993;45:291-293.
49. Van Hecken A, Depre M, Verbesselt R, et al. Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. *J Clin Pharmacol*. 1999;39:495-500.
50. Anderson DM, Shelley S, Crick N, Buraglio M. No effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers. *J Clin Pharmacol*. 2002;42:1358-1365.
51. Salazar DE, Dockens RC, Milbrath RL, et al. Pharmacokinetic and pharmacodynamic evaluation of warfarin and nefazodone coadministration in healthy subjects. *J Clin Pharmacol*. 1995;35:730-738.
52. Duursema L, Muller FO, Schall R, et al. Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin. *Br J Clin Pharmacol*. 1995;39:700-703.
53. Burke S, Amin N, Incerti C, Plone M, Watson N. Sevelamer hydrochloride a nonabsorbed phosphate-binding polymer does not interfere with digoxin or warfarin pharmacokinetics. *J Clin Pharmacol*. 2001;41:193-198.
54. Byrd DC, Gaskins SE, Parrish AM, Freeman LB. Warfarin and ciprofloxacin interaction: case report and controversy. *J Am Board Fam Pract*. 1999;12:486-488.
55. McMorran M, Morawiecka I. Celecoxib (Celebrex): 1 year later. *CMAJ*. 2000;162:1044-1046, 1048-1050.
56. Dent LA, Orrock MW. Warfarin-fluoxetine and diazepam-fluoxetine interaction. *Pharmacotherapy*. 1997;17:170-172.
57. Guerret M, Francheteau P, Huber M. Evaluation of effects of terbinafine on single oral dose pharmacokinetics and anticoagulant actions of warfarin in healthy volunteers. *Pharmacotherapy*. 1997;17:767-773.
58. Warwick JA, Corral RJ. Serious interaction between warfarin and oral terbinafine. *BMJ*. 1998;316:440.
59. Gupta AK, Ross GS. Interaction between terbinafine and warfarin. *Dermatology*. 1998;196:266-267.
60. Newsham G, Tsang P. Ritonavir and warfarin interaction. *AIDS*. 1999;13:1788-1789.
61. Poli D, Chiarugi L, Capanni M, et al. Need of more frequent international normalized ratio monitoring in elderly patients on long-term anticoagulant therapy after influenza vaccination. *Blood Coagul Fibrinolysis*. 2002;13:297-300.
62. Lipsky BA, Pecoraro RE, Roben NJ, de Blaquiere P, Delaney CJ. Influenza vaccination and warfarin anticoagulation. *Ann Intern Med*. 1984;100:835-837.
63. Kramer P, Tsuru M, Cook CE, McClain CJ, Holtzman JL. Effect of influenza vaccine on warfarin anticoagulation. *Clin Pharmacol Ther*. 1984;35:416-418.
64. Duursema L, Muller FO, Hundt HK, Heyns AD, Meyer BH, Luus HG. Model to detect warfarin-drug interactions in man. *Drug Investig*. 1992;4:395-402.
65. Heimark LD, Wienkers L, Kunze K, et al. The mechanism of the interaction between amiodarone and warfarin in humans. *Clin Pharmacol Ther*. 1992;51:398-407.
66. Almog S, Shafran N, Halkin H, et al. Mechanism of warfarin potentiation by amiodarone: dose and concentration-dependent inhibition of warfarin elimination. *Eur J Clin Pharmacol*. 1985;28:257-261.
67. O'Reilly RA, Trager WF, Rettie AE, Goulart DA. Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans. *Clin Pharmacol Ther*. 1987;42:290-294.
68. Pyorala K, Myllyla G, Kekki M. Metabolism of warfarin during methandrostenolone treatment. *Ann Med Exp Biol Fenn*. 1965;43:95-97.
69. Lorentz SM, Weibert RT. Potentiation of warfarin anticoagulation by topical testosterone ointment. *Clin Pharm*. 1985;4:332-334.
70. Toon S, Hopkins KJ, Garstang FM, Rowland M. Comparative effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of warfarin in man. *Eur J Clin Pharmacol*. 1987;32:165-172.
71. O'Reilly RA. Comparative interaction of cimetidine and ranitidine with racemic warfarin in man. *Arch Intern Med*. 1984;144:989-991.
72. Bell WR, Anderson KC, Noe DA, Silver BA. Reduction in the plasma clearance rate of warfarin induced by cimetidine. *Arch Intern Med*. 1986;146:2325-2328.

73. Serlin MJ, Sibeon RG, Mossman S, et al. Cimetidine: interaction with oral anticoagulants in man. *Lancet*. 1979;2:317-319.
74. Sax MJ, Randolph WC, Peace KE, et al. Effect of two cimetidine regimens on prothrombin time and warfarin pharmacokinetics during long-term warfarin therapy [published correction appears in *Clin Pharm*. 1988;7:269]. *Clin Pharm*. 1987;6:492-495.
75. Hunt BA, Sax MJ, Chretien S, Frank WO, Braverman AJ. Stereoselective alterations in the pharmacokinetics of warfarin enantiomers with two cimetidine dose regimens. *Pharmacotherapy*. 1989;9:184.
76. O'Reilly RA, Sahud MA, Robinson AJ. Studies on the interaction of warfarin and clofibrate in man. *Thromb Diath Haemorrh*. 1972;27:309-318.
77. O'Reilly RA, Motley CH. Racemic warfarin and trimethoprim-sulfamethoxazole interaction in humans. *Ann Intern Med*. 1979;91:34-36.
78. Weibert RT, Lorentz SM, Townsend RJ, Cook CE, Klauber MR, Jagger PI. Effect of erythromycin in patients receiving long-term warfarin therapy. *Clin Pharm*. 1989;8:210-214.
79. Black D, Evans J, Seaton T, Gidal B, McDonnell N, Kunze K. Evaluation of the effect of fluconazole on the stereoselective metabolism of warfarin [abstract]. *Clin Pharmacol Ther*. 1992; 51:pii-52.
80. Rosenthal AR, Self TH, Baker ED, Linden RA. Interaction of isoniazid and warfarin. *JAMA*. 1977; 238:2177.
81. O'Reilly RA. The stereoselective interaction of warfarin and metronidazole in man. *N Engl J Med*. 1976;295:354-357.
82. O'Reilly RA, Goulart DA, Kunze KL, et al. Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects. *Clin Pharmacol Ther*. 1992; 51:656-667.
83. Suttin T, Balmer K, Bostrom H, Eriksson S, Hoglund P, Paulsen O. Stereoselective interaction of omeprazole with warfarin in healthy men. *Ther Drug Monit*. 1989;11:176-184.
84. Aggeler PM, O'Reilly RA, Leong L, Kowitz PE. Potentiation of anticoagulant effect of warfarin by phenylbutazone. *N Engl J Med*. 1967;276: 496-501.
85. O'Reilly RA, Trager WF, Motley CH, Howald W. Stereoselective interaction of phenylbutazone with [<sup>12</sup>C/<sup>13</sup>C] warfarin pseudoracemates in man. *J Clin Invest*. 1980;65:746-753.
86. Rhodes RS, Rhodes PJ, Klein C, Sintek CD. A warfarin-piroxicam drug interaction. *Drug Intell Clin Pharm*. 1985;19:556-558.
87. Kates RE, Yee YG, Kirsten EB. Interaction between warfarin and propafenone in healthy volunteer subjects. *Clin Pharmacol Ther*. 1987; 42:305-311.
88. Scott AK, Park BK, Breckenridge AM. Interaction between warfarin and propranolol. *Br J Clin Pharmacol*. 1984;17(suppl 1):86S.
89. Bax ND, Lennard MS, Tucker GT, et al. The effect of beta-adrenoceptor antagonists on the pharmacokinetics and pharmacodynamics of warfarin. *Br J Clin Pharmacol*. 1984;17(suppl 1):85S.
90. Nenci GG, Agnelli G, Berrettini M. Biphasic sulphinpyrazone-warfarin interaction. *Br Med J (Clin Res Ed)*. 1981;282:1361-1362.
91. O'Reilly RA. Stereoselective interaction of sulfinpyrazone with racemic warfarin and its separated enantiomorphs in man. *Circulation*. 1982; 65:202-207.
92. Toon S, Low LK, Gibaldi M, et al. The warfarin-sulfinpyrazone interaction: stereochemical considerations. *Clin Pharmacol Ther*. 1986; 39:15-24.
93. O'Reilly RA, Trager WF, Motley CH, Howald W. Interaction of secobarbital with warfarin pseudoracemates. *Clin Pharmacol Ther*. 1980; 28:187-195.
94. Orme M, Breckenridge A. Enantiomers of warfarin and phenobarbital. *N Engl J Med*. 1976; 295:1482-1483.
95. Hansen JM, Siersboek-Nielsen K, Skovsted L. Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man. *Clin Pharmacol Ther*. 1971;12:539-543.
96. Breckenridge A, Orme M. Clinical implications of enzyme induction. *Ann N Y Acad Sci*. 1971; 179:421-430.
97. Robinson DS, Benjamin DM, McCormack JJ. Interaction of warfarin and non-systemic gastrointestinal drugs. *Clin Pharmacol Ther*. 1971; 12:491-495.
98. Jahnchen E, Meinertz T, Gilfrich HJ, Kersting F, Groth U. Enhanced elimination of warfarin during treatment with cholestyramine. *Br J Clin Pharmacol*. 1978;5:437-440.
99. Okino K, Weibert RT. Warfarin-griseofulvin interaction. *Drug Intell Clin Pharm*. 1986; 20:291-293.
100. Cullen SI, Catalano P. Griseofulvin-warfarin antagonism. *JAMA*. 1967;199:582-583.
101. Qureshi GD, Reinders TP, Somori GJ, Evans HJ. Warfarin resistance with nafcillin therapy. *Ann Intern Med*. 1984;100:527-529.
102. O'Reilly RA. Interaction of sodium warfarin and rifampin: studies in man. *Ann Intern Med*. 1974; 81:337-340.
103. Heimark LD, Gibaldi M, Trager WF, O'Reilly RA, Goulart DA. The mechanism of the warfarin-rifampin drug interaction in humans. *Clin Pharmacol Ther*. 1987;42:388-394.
104. Mungall D, Talbert RL, Phillips C, Jaffe D, Ludden TM. Sucralfate and warfarin [letter]. *Ann Intern Med*. 1983;98:557.
105. Talbert RL, Dalmady-Israel C, Bussey HI, Crawford MH, Ludden TM. Effect of sucralfate on plasma warfarin concentration in patients requiring chronic warfarin therapy. *Drug Intell Clin Pharm*. 1985;19:59.
106. Qureshi GD, Reinders TP, Swint JJ, Slate MB. Acquired warfarin resistance and weight-reducing diet. *Arch Intern Med*. 1981;141: 507-509.
107. Parr MD, Record KE, Griffith GL, Zeok JV, Todd EP. Effect of enteral nutrition on warfarin therapy. *Clin Pharm*. 1982;1:274-276.
108. Blickstein D, Shaklai M, Inbal A. Warfarin antagonism by avocado [letter]. *Lancet*. 1991; 337:914-915.
109. O'Reilly RA. Lack of effect of fortified wine ingested during fasting and anticoagulant therapy. *Arch Intern Med*. 1981;141:458-459.
110. O'Reilly RA. Lack of effect of mealtime wine on the hypoprothrombinemia of oral anticoagulants. *Am J Med Sci*. 1979;277:189-194.
111. Nipper H, Kirby S, Iber FL. Effect of bumetanide on the serum disappearance of warfarin sodium. *J Clin Pharmacol*. 1981;21:654-656.
112. Serlin MJ, Mossman S, Sibeon RG, Tempero KF, Breckenridge AM. Interaction between diflunisal and warfarin. *Clin Pharmacol Ther*. 1980; 28:493-498.
113. Toon S, Hopkins KJ, Garstang FM, Aarons L, Sedman A, Rowland M. Enoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects. *Clin Pharmacol Ther*. 1987;42:33-41.
114. De Lepeleire I, Van Hecken A, Verbesselt R, et al. Lack of interaction between famotidine and warfarin. *Int J Clin Pharmacol Res*. 1990; 10:167-171.
115. Grind M, Murphy M, Warrington S, Aberg J. Method for studying drug-warfarin interactions. *Clin Pharmacol Ther*. 1993;54:381-387.
116. Rowe H, Carmichael R, Lemberger L. The effect of flouxetine on warfarin metabolism in the rat and man. *Life Sci*. 1978;23:807-812.
117. Toon S, Holt BL, Mullins FG, Bullingham R, Aarons L, Rowland M. Investigations into the potential effects of multiple dose ketorolac on the pharmacokinetics and pharmacodynamics of racemic warfarin. *Br J Clin Pharmacol*. 1990;30: 743-750.
118. Benedek IH, King SY, Powell RJ, Agra AM, Schary WL, Pieniazek HJ Jr. Effect of moricizine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. *J Clin Pharmacol*. 1992;32:558-563.
119. Jain A, MacMahon FG, Slattery JT, Levy G. Effect of naproxen on the steady-state serum concentration and anticoagulant activity of warfarin. *Clin Pharmacol Ther*. 1979;25:61-66.
120. Cournot A, Berlin I, Sallord JC, Singlas E. Lack of interaction between nizatidine and warfarin during chronic administration. *J Clin Pharmacol*. 1988;28:1120-1122.
121. Serlin MJ, Sibeon RG, Breckenridge AM. Lack of effect of ranitidine on warfarin action. *Br J Clin Pharmacol*. 1981;12:791-794.
122. Orme M, Breckenridge A, Cook P. Warfarin and distalgesic interaction. *BMJ*. 1976;1:200.
123. Davydov L, Yermolnik M, Cuni LJ. Warfarin and amoxicillin/clavulanate drug interaction. *Ann Pharmacother*. 2003;37:367-370.
124. Foster DR, Milani NL. Potential interaction between azithromycin and warfarin. *Pharmacotherapy*. 1999;19:902-908.
125. Udall JA. Warfarin interactions with chloral hydrate and glutethimide. *Curr Ther Res Clin Exp*. 1975;17:67-74.
126. Byers M. Clarithromycin-warfarin interaction resulting in an elevated INR. *Can J Hosp Pharm*. 1997;50:285-287.
127. Izzat MB, Yim AP, El Zufari MH. A taste of Chinese medicine. *Ann Thorac Surg*. 1998;66: 941-942.
128. Smith R, Prudden D, Hawkes C. Propoxyphene and warfarin interaction [letter]. *Drug Intell Clin Pharm*. 1984;18:822.
129. O'Reilly RA. Dynamic interaction between disulfiram and separated enantiomorphs of racemic warfarin. *Clin Pharmacol Ther*. 1981;29:332-336.
130. Page RL, Lawrence JD. Potentiation of warfarin by dong quai. *Pharmacotherapy*. 1999;19: 870-876.
131. Carabino J, Wang F. International normalized ratio fluctuation with warfarin-fluorouracil therapy [letter]. *Am J Health Syst Pharm*. 2002;59: 875.
132. Trilli LE, Kelley CL, Aspinall SL, Kroner BA. Potential interaction between warfarin and fluvastatin. *Ann Pharmacother*. 1996;30:1399-1402.
133. Limke KK, Shelton AR, Elliott ES. Fluvoxamine interaction with warfarin. *Ann Pharmacother*. 2002;36:1890-1892.
134. Kinikar SA, Kolesar JM. Identification of a gemcitabine-warfarin interaction. *Pharmacotherapy*. 1999;19:1331-1333.
135. Bartle WR. Grapefruit juice might still be factor in warfarin response [letter]. *Am J Health Syst Pharm*. 1999;56:676.

136. Adachi Y, Yokoyama Y, Nanno T, Yamamoto T. Potentiation of warfarin by interferon. *BMJ*. 1995; 311:292.
137. Yeh J, Soo SC, Summerton C, Richardson C. Potentiation of action of warfarin by itraconazole. *BMJ*. 1990;301:669.
138. Scarfe MA, Israel MK. Possible drug interaction between warfarin and combination of levamisole and fluorouracil. *Ann Pharmacother*. 1994; 28:464-467.
139. Ravnan SL, Locke C. Levofloxacin and warfarin interaction. *Pharmacotherapy*. 2001;21:884-885.
140. Lam AY, Elmer GW, Mohutsky MA. Possible interaction between warfarin and Lycium barbarum L. *Ann Pharmacother*. 2001;35:1199-1201.
141. Davis NB, Nahlik L, Vogelzang NJ. Does PC-SPES interact with warfarin? *J Urol*. 2002; 167:1793.
142. Thompson ME, Highley MS. Interaction between paclitaxel and warfarin [letter]. *Ann Oncol*. 2003;14:500.
143. Fitzmaurice DA, Murray JA. Potentiation of the anticoagulant effect of warfarin. *Postgrad Med J*. 1997;73:439-440.
144. Levine M, Sheppard I. Biphasic interaction of phenytoin with warfarin. *Clin Pharm*. 1984;3: 200-203.
145. Koch-Weser J. Quinidine-induced hypoprothrombinemic hemorrhage in patients on chronic warfarin therapy. *Ann Intern Med*. 1968;68:511-517.
146. Bair JD, Oppelt TF. Warfarin and ropinirole interaction. *Ann Pharmacother*. 2001;35:1202-1204.
147. Gaw A, Wosornu D. Simvastatin during warfarin therapy in hyperlipoproteinaemia [letter]. *Lancet*. 1992;340:979-980.
148. Lin JC, Ito MK, Stolley SN, Morreale AP, Marcus DB. The effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin. *J Clin Pharmacol*. 1999;39:86-90.
149. Lodwick R, McConkey B, Brown AM. Life threatening interaction between tamoxifen and warfarin. *Br Med J (Clin Res Ed)*. 1987;295:1141.
150. Westfall LK. An unrecognized cause of warfarin resistance [letter]. *Drug Intell Clin Pharm*. 1981; 15:131.
151. Danos EA. Apparent potentiation of warfarin activity by tetracycline. *Clin Pharm*. 1992;11: 806-808.
152. Colucci VJ, Rivey MP. Tolterodine-warfarin drug interaction. *Ann Pharmacother*. 1999;33:1173-1176.
153. Sabbe JR, Sims PJ, Sims MH. Tramadol-warfarin interaction. *Pharmacotherapy*. 1998; 18:871-873.
154. Scher ML, Huntington NH, Vitillo JA. Potential interaction between tramadol and warfarin [letter]. *Ann Pharmacother*. 1997;31:646-647.
155. Plowman BK, Morreale AP. Possible troglitazone-warfarin interaction [letter]. *Am J Health Syst Pharm*. 1998;55:1071.
156. Rotenberg M, Levy Y, Shoenfeld Y, Almog S, Ezra D. Effect of azathioprine on the anticoagulant activity of warfarin. *Ann Pharmacother*. 2000; 34:120-122.
157. Murphey LM, Hood EH. Bosentan and warfarin interaction. *Ann Pharmacother*. 2003;37:1028-1031.
158. Jonkman JH, van Lier JJ, van Heiningen PN, Lins R, Sennewald R, Hogemann A. Pharmacokinetic drug interaction studies with candesartan cilexetil. *J Hum Hypertens*. 1997;11(suppl 2):S31-S35.
159. Grebe HB, Gregory PJ. Inhibition of warfarin anticoagulation associated with chelation therapy. *Pharmacotherapy*. 2002;22:1067-1069.
160. Krstenansky PM, Jones WN, Garewal HS. Effect of dicloxacillin sodium on the hypoprothrombinemic response to warfarin sodium. *Clin Pharm*. 1987;6:804-806.
161. Mailloux AT, Gidal BE, Sorkness CA. Potential interaction between warfarin and dicloxacillin. *Ann Pharmacother*. 1996;30:1402-1407.
162. Rosado MF. Thrombosis of a prosthetic aortic valve disclosing a hazardous interaction between warfarin and a commercial ginseng product. *Cardiology*. 2003;99:111.
163. Kurnik D, Lubetsky A, Loebstein R, Almog S, Halkin H. Multivitamin supplements may affect warfarin anticoagulation in susceptible patients. *Ann Pharmacother*. 2003;37:1603-1606.
164. Miller JW, Skerjanc A, Knadler MP, Ghosh A, Allerheiligen SRB. Divergent effects of raloxifene HCl on the pharmacokinetics and pharmacodynamics of warfarin. *Pharm Res*. 2001; 18:1024-1028.
165. Knoell KR, Young TM, Cousins ES. Potential interaction involving warfarin and ritonavir. *Ann Pharmacother*. 1998;32:1299-1302.
166. Cambria-Kiely JA. Effect of soy milk on warfarin efficacy. *Ann Pharmacother*. 2002;36: 1893-1896.
167. Stern R, Abel R, Gibson GL, Besserer J. Atorvastatin does not alter the anticoagulant activity of warfarin. *J Clin Pharmacol*. 1997;37: 1062-1064.
168. Kelly J, Murdoch RD, Clark DJ, Webber DM, Fuder H. Warfarin pharmacodynamics unaffected by cilomilast. *Ann Pharmacother*. 2001;35:1535-1539.
169. Donovan JM, Stypinski D, Stiles MR, Olson TA, Burke SK. Drug interactions with colesevelam hydrochloride: a novel potent lipid-lowering agent. *Cardiovasc Drugs Ther*. 2000;14:681-690.
170. Schulman S, Henriksson K. Interaction of ibuprofen and warfarin on primary haemostasis. *Br J Rheumatol*. 1989;28:46-49.
171. Brass C, Galgiani JN, Blaschke TF, Defelice R, O'Reilly RA, Stevens DA. Disposition of ketoconazole an oral antifungal in humans. *Antimicrob Agents Chemother*. 1982;21:151-158.
172. Mieszczyk C, Winther K. Lack of interaction of ketoprofen with warfarin. *Eur J Clin Pharmacol*. 1993;44:205-206.
173. Antila S, Jarvinen A, Honkanen T, Lehtonen L. Pharmacokinetic and pharmacodynamic interactions between the novel calcium sensitizer levosimendan and warfarin. *Eur J Clin Pharmacol*. 2000;56:705-710.
174. Morreale AP, Janetzky K. Probable interaction of warfarin and acarbose. *Am J Health Syst Pharm*. 1997;54:1551-1552.
175. Woeber KA, Warner I. Potentiation of warfarin sodium by amiodarone-induced thyrotoxicosis. *West J Med*. 1999;170:49-51.
176. Bandrowsky T, Vorono AA, Borris TJ, Marcantoni HW. Amoxicillin-related postextraction bleeding in an anticoagulated patient with tranexamic acid rinses. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 1996;82:610-612.
177. Malacarne P, Maestri A. Possible interactions between antiplastic agents and warfarin inducing prothrombin time abnormalities [letter]. *Recenti Prog Med*. 1996;87:135.
178. Leone R, Ghiotto E, Conforti A, Velo G. Potential interaction between warfarin and ocular chloramphenicol [letter]. *Ann Pharmacother*. 1999; 33:114.
179. Suvarna R, Pirmohamed M, Henderson L. Possible interaction between warfarin and cranberry juice. *BMJ*. 2003;327:1454.
180. Yue Q, Jansson K. Herbal drug curcubin and anticoagulant effect with and without warfarin: possibly related to the vitamin E component [letter]. *J Am Geriatr Soc*. 2001;49:838.
181. Booth CD. Drug interaction between danazol and warfarin. *Pharm J*. 1993;250:439-440.
182. Tam LS, Chan TY, Leung WK, Critchley JA. Warfarin interactions with Chinese traditional medicines: danshen and methyl salicylate medicated oil [letter]. *Aust N Z J Med*. 1995;25: 258.
183. Sylvén C, Anderson P. Evidence that disopyramide does not interact with warfarin. *Br Med J (Clin Res Ed)*. 1983;286:1181.
184. Haworth E, Burroughs AK. Disopyramide and warfarin interaction. *BMJ*. 1977;2:866-867.
185. Tisdell KA, Israel DS, Kolb KW. Warfarin-felbamate interaction: first report [letter]. *Ann Pharmacother*. 1994;28:805.
186. Artymowicz RJ, Cino BJ, Rossi JG, Walker JL, Moore S. Possible interaction between gatifloxacin and warfarin. *Am J Health Syst Pharm*. 2002; 59:1205-1206.
187. Rindone JP, Keng HC. Gemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia. *Chest*. 1998;114:641-642.
188. Chan TY, Lui SF, Chung SY, Luk S, Critchley JA. Adverse interaction between warfarin and indomethacin. *Drug Saf*. 1994;10:267-269.
189. Hall G, Lind MJ, Huang M, et al. Intravenous infusions of ifosfamide/mesna and perturbation of warfarin anticoagulant control. *Postgrad Med J*. 1990;66:860-861.
190. Ahmad S. Lovastatin: warfarin interaction. *Arch Intern Med*. 1990;150:2407.
191. Lim V, Pande I. Leflunomide can potentiate the anticoagulant effect of warfarin. *BMJ*. 2002; 325:1333.
192. Trewin VF. A probable interaction between warfarin and metolazone. *Pharm J*. 1988;18:781-782.
193. Evans J, Orme DS, Sedgwick ML, Youngs GR. Treating oral candidiasis: potentially fatal [letter]. *Br Dent J*. 1997;182:452.
194. Leor J, Levartovsky D, Sharon C. Interaction between nalidixic acid and warfarin [letter]. *Ann Intern Med*. 1987;107:601.
195. Linville T, Matanin D. Norfloxacin and warfarin. *Ann Intern Med*. 1989;110:751-752.
196. Leor J, Matetzki S. Ofloxacin and warfarin [letter]. *Ann Intern Med*. 1988;109:761.
197. Baciewicz AM, Ashar BH, Locke TW. Interaction of ofloxacin and warfarin [letter]. *Ann Intern Med*. 1993;119:1223.
198. MacWalter RS, Fraser HW, Armstrong KM. Orlistat enhances warfarin effect. *Ann Pharmacother*. 2003;37:510-512.
199. Littleton F. Warfarin and topical salicylates [letter]. *JAMA*. 1990;263:2888.
200. Chow WH, Cheung KL, Ling HM, See T. Potentiation of warfarin anticoagulation by topical methylsalicylate ointment. *J R Soc Med*. 1989; 82:501-502.
201. Darlington MR. Hypoprothrombinemia during concomitant therapy with warfarin and saquinavir [letter]. *Ann Pharmacother*. 1997;31:647.
202. Carter SA. Potential effect of sulindac on response of prothrombin-time to oral anticoagulants. *Lancet*. 1979;2:698-699.
203. Ross JR, Beeley L. Sulindac prothrombin time and anticoagulants [letter]. *Lancet*. 1979; 2:1075.

204. Gidal BE, Sorkness CA, McGill KA, Larson R, Levine RR. Evaluation of a potential enantioselective interaction between ticlopidine and warfarin in chronically anticoagulated patients. *Ther Drug Monit.* 1995;17:33-38.
205. Koren JF, Cochran DL, Janes RL. Tolmetin-warfarin interaction. *Am J Med.* 1987;82:1278-1280.
206. Nissenblatt MJ, Karp GI. Bleeding risk with trastuzumab (Herceptin) treatment. *JAMA.* 1999;282:2299-2301.
207. Snyder DS. Interaction between cyclosporine and warfarin [letter]. *Ann Intern Med.* 1988;108:311.
208. Ostlere LS, Langtry JA, Jones S, Staughton RC. Reduced therapeutic effect of warfarin caused by etretinate [letter]. *Br J Dermatol.* 1991;124:505.
209. Teefy AM, Martin JE, Kovacs MJ. Warfarin resistance due to sulfasalazine. *Ann Pharmacother.* 2000;34:1265-1268.
210. Bartle WR, Madorin P, Guylaine F. Seaweed, vitamin K, and warfarin [letter]. *Am J Health Syst Pharm.* 2001;58:2300.
211. Stangier J, Su CA, Hendriks MG, et al. Steady-state pharmacodynamics and pharmacokinetics of warfarin in the presence and absence of telmisartan in healthy male volunteers. *J Clin Pharmacol.* 2000;40:1331-1337.
212. Spigset O. Reduced effect of warfarin caused by ubidecarenone [letter]. *Lancet.* 1994;344:1372-1373.
213. Beringer TR. Warfarin potentiation with bezafibrate. *Postgrad Med J.* 1997;73:657-658.
214. Angaran DM, Dias VC, Arom KV, et al. The comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the post-operative prosthetic cardiac valve patient: cefamandole cefazolin vancomycin. *Ann Surg.* 1987;206:155-161.
215. Le AT, Hasson NK, Lum BL. Enhancement of warfarin response in a patient receiving etoposide and carboplatin chemotherapy. *Ann Pharmacother.* 1997;31:1006-1008.
216. Thomas P, Fennerty A, Blackhouse G. Oral anticoagulant during treatment with heparin. *Br Med J (Clin Res Ed).* 1984;288:191.
217. Wehbe TW, Warth JA. A case of bleeding requiring hospitalization that was likely caused by an interaction between warfarin and levamisole. *Clin Pharmacol Ther.* 1996;59:360-362.
218. Ellison J. Apparent interaction between warfarin and levonorgestrel used for emergency contraception. *BMJ.* 2000;321:1382.
219. Kaufman M. Treatment of multiple sclerosis with high-dose corticosteroids may prolong the prothrombin time to dangerous levels in patients taking warfarin. *Mult Scler.* 1997;3:248-249.
220. Dennis VC, Thomas BK, Hanlon JE. Potentiation of oral anticoagulation and hemarthrosis associated with nabumetone. *Pharmacotherapy.* 2000;20:234-239.
221. Rogers T, de Leon J, Atcher D. Possible interaction between warfarin and quetiapine [letter]. *J Clin Psychopharmacol.* 1999;19:382-383.
222. Sioris LJ, Weibert RT, Pentel PR. Potentiation of warfarin anticoagulation by sulfisoxazole. *Arch Intern Med.* 1980;140:546-547.
223. Ibrahim OM, Allam A. Warfarin resistance in a patient with prosthetic valve endocarditis treated with cloxacillin. *Saudi Pharm J.* 1996;4:56-59.
224. Laizure SC, Madlock L, Cyr M, Self T. Decreased hypoprothrombinemic effect of warfarin associated with furosemide. *Ther Drug Monit.* 1997;19:361-363.
225. Taylor JR, Wilt VM. Probable antagonism of warfarin by green tea. *Ann Pharmacother.* 1999;33:426-428.
226. Setter SM, Lawless K, Hunter KA. Need for continuity of care in patients receiving warfarin and nafcillin/dicloxacillin. *Hosp Pharm.* 1996;31:1269-1271.
227. MacLaren R, Wachsmann BA, Swift DK, Kuhl DA. Warfarin resistance associated with intravenous lipid administration: discussion of propofol and review of the literature. *Pharmacotherapy.* 1997;17:1331-1337.
228. Agosta FG, Liberato NL, Chiofalo F. Warfarin resistance induced by teicoplanin [letter]. *Haematologica.* 1997;82:637-638.
229. May JR, DiPiro JT, Sisley JF. Drug interactions in surgical patients. *Am J Surg.* 1987;153:327-335.
230. Gabb GM. Fatal outcome of interaction between warfarin and a non-steroidal anti-inflammatory drug [letter]. *Med J Aust.* 1996;164:700-701.
231. Baciewicz AM, Menke JJ, Bokar JA, Baud EB. Fluconazole-warfarin interaction [letter]. *Ann Pharmacother.* 1994;28:1111.
232. Haase KK, Rojas-Fernandez CH, Lane L, Frank DA. Potential interaction between celecoxib and warfarin. *Ann Pharmacother.* 2000;34:666-667.
233. Janetzky K, Morreale AP. Probable interaction between warfarin and ginseng. *Am J Health Syst Pharm.* 1997;54:692-693.
234. Holbrook AM, Wells PS, Crowther NR. Pharmacokinetics and drug interactions with warfarin. In: Poller L, Hirsh J, eds. *Oral Anticoagulants.* Dunton Green, England: Hodder and Stoughton; 1996.
235. Indiana University Department of Medicine Web site. Cytochrome P450 drug interaction table. Available at: <http://medicine.iupui.edu/flockhart/table.htm>. Accessed July 15, 2004.
236. O'Reilly RA. Stereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man. *N Engl J Med.* 1980;302:33-35.
237. Hirsh J, Ansell J, Ansell J, Halperin JL. American Heart Association/American College of Cardiology foundation guide to warfarin therapy. *Circulation.* 2003;107:1692-1711.
238. Harris JE. Interaction of dietary factors with oral anticoagulants: review and applications. *J Am Diet Assoc.* 1995;95:580-584.
239. O'Reilly RA, Ryland D. "Resistance" to warfarin due to unrecognized vitamin K supplementation [letter]. *N Engl J Med.* 1980;303:160-161.
240. Pedersen FM, Hamburg O, Hess K, Ovesen L. The effect of dietary vitamin K on warfarin-induced anticoagulants. *J Intern Med.* 1991;229:517-520.
241. Owens JC, Neely JB, Owen WR. Effect of sodium dextrothroxine in patients receiving anticoagulation. *N Engl J Med.* 1962;266:76-79.
242. Antlitz AM, Mead JA Jr, Tolentino MA. Potentiation of oral anticoagulant therapy by acetaminophen. *Curr Ther Res Clin Exp.* 1968;10:501-507.
243. Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. Acetaminophen and other risk factors for excessive warfarin anticoagulation. *JAMA.* 1998;279:657-662.
244. Kwan D, Bartle WR, Walker SE. The effects of acetaminophen on pharmacokinetics and pharmacodynamics of warfarin. *J Clin Pharmacol.* 1999;39:68-75.
245. Gianni LM, Dreitlein WB. Some popular OTC herbals can interact with anticoagulant therapy. *US Pharm.* 1998;23:80, 83-84, 86.
246. Joshi BS, Kaul PN. Alternative medicine: herbal drugs and their critical appraisal—part I. *Prog Drug Res.* 2001;56:1-76.
247. Holbrook AM, Janjusevic V, Keshavjee K, Lee HK. Measuring quality of prescribing: where does the information reside? [abstract]. *Can J Clin Pharmacol.* 2002;9:40.
248. Holbrook AM, Keshavjee K, Goldsmith CH, Tucker J, Park L. Advancing the measurement of quality of care using electronic medical records. *Proc Towards Electron Patient Rec.* 1999;1:848-855.